Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
FVC · adults and children with cystic fibrosis
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).
2 findings from 1 review
Exacerbations · adults and children with cystic fibrosis
Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).
1 finding from 1 review
Incidence of S pneumoniae infection Isolated bacterial infection · children with SCD
Summary of findings ‐ initiation of penicillin prophylaxis may leads to lower incidence of S pneumoniae infection Isolated bacterial infection compared with placebo (low certainty).
1 finding from 1 review
Deaths · children with SCD
Summary of findings ‐ initiation of penicillin prophylaxis showed no clear difference in deaths compared with placebo (low certainty).
1 finding from 1 review
Adverse effects · children with SCD
1 finding from 1 review
Antibiotic‐resistant organisms isolated · children with SCD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requirement of other courses of antibiotics · children with SCD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Compliance with treatment · children with SCD
1 finding from 1 review
Change in height · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in longitudinal growth: change in height SDS compared with placebo or no intervention (low certainty).
1 finding from 1 review
Measures of mineral metabolism: change in serum phosphate mmol/L · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of mineral metabolism: change in serum phosphate mmol/L compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Alkaline phosphatase · children with X‐linked hypophosphataemia
1 finding from 1 review
Measures of renal function: change in TmP/GFR · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of renal function: change in TmP/GFR compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Body proportions: sitting height SDS · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse effects · children with X‐linked hypophosphataemia
1 finding from 1 review
Ulcer healing · individuals with sickle cell disease and a leg ulcer
It is very uncertain whether isoxsuprine changes complete leg ulcer closure (defined as 100% epithelization or skin… compared with placebo (very low certainty).
1 finding from 1 review
Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found